Table 2.
TLR2 expression on CD19+/CD5+ of CLL patients and healthy controls
| CD19+/CD5+/TLR2+ (%) Median (range) |
CD19+/CD5+/TLR2+ (MFI) Median (range) |
|
|---|---|---|
| Healthy volunteers PB | 1.58 (1.16–36.73) | 72.53 (37.84–139.30) |
| CLL patients PB | 0.38 (0.02–63.06) | 39.70 (15.77–161.80) |
| Low risk (stage 0) | 0.52 (0.04–63.06) | 68.87 (20.27–161.80) |
| Intermediate-risk (stage I/II) | 0.29 (0.03–37.76) | 57.02 (20.75–143.50) |
| High-risk (stage III/IV) | 0.30 (0.02–60.46) | 37.86 (15.77–139.30) |
| ZAP-70− | 1.64 (0.02–63.06) | 65.52 (28.19–161.80) |
| ZAP-70+ | 0.26 (0.03–48.88) | 45.89 (15.77–143.50) |
| CD38− | 0.98 (0.02–63.06) | 65.50 (28.19–161.80) |
| CD38+ | 0.26 (0.03–48.88) | 44.28 (15.77–143.50) |
| del(17p13.1) and/or del(11q22.3) | 0.24 (0.02–48.88) | 55.88 (15.77–143.50) |
| Without del(17p13.1) and del(11q22.3) | 0.49 (0.09–60.46) | 68.84 (44.59–108.00) |
| Isolated del(13q14) | 0.72 (0.04–63.06) | 67.80 (28.19–161.80) |
| CLL patients requiring therapy | 0.29 (0.02–60.46) | 62.03 (15.77–139.25) |
| Untreated CLL patients | 0.44 (0.04–63.06) | 66.84 (31.00–161.80) |
CLL patients were divided according to adverse prognostic factors, MFI mean fluorescence intensity, PB peripheral blood